Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$39.78 +0.3%	$35.29	$21.62 ▼ $40.40	$7.55B	1.1	2.49 million shs	2.64 million shs
CGON CG Oncology	$25.86 -2.4%	$24.04	$14.80 ▼ $40.47	$1.97B	0.86	836,586 shs	626,383 shs
ROIV Roivant Sciences	$11.32 -1.3%	$10.81	$8.73 ▼ $13.06	$7.70B	1.16	5.59 million shs	5.97 million shs
RVMD Revolution Medicines	$40.59 -1.3%	$38.85	$29.17 ▼ $62.40	$7.56B	1.1	1.53 million shs	1.09 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+0.33%	+3.00%	+18.18%	+20.66%	+38.70%
CGON CG Oncology	-2.42%	-3.90%	+6.99%	-6.98%	-27.18%
ROIV Roivant Sciences	-1.31%	+0.80%	+6.09%	+6.19%	+4.52%
RVMD Revolution Medicines	-1.26%	-1.22%	+2.81%	+3.76%	+1.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.5561 of 5 stars	4.5	2.0	3.9	2.1	3.3	0.6
CGON CG Oncology	2.5144 of 5 stars	4.5	1.0	0.0	3.0	0.8	0.0
ROIV Roivant Sciences	2.357 of 5 stars	3.5	3.0	0.0	1.9	2.5	0.0
RVMD Revolution Medicines	4.4387 of 5 stars	4.5	1.0	4.7	3.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$57.36	44.20% Upside
CGON CG Oncology	3.00	Buy	$58.22	125.14% Upside
ROIV Roivant Sciences	3.00	Buy	$17.50	54.59% Upside
RVMD Revolution Medicines	3.00	Buy	$67.08	65.27% Upside

Current Analyst Ratings Breakdown

Latest CGON, ROIV, RVMD, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/19/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $52.00
5/14/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $72.00
5/8/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00
5/8/2025	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $75.00
5/8/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$87.00 ➝ $80.00
5/8/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00 ➝ $57.00
5/2/2025	CGON CG Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$41.00
4/30/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$46.00 ➝ $63.00
4/30/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $55.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$127.42M	59.28	N/A	N/A	($7.71) per share	-5.16
CGON CG Oncology	$662K	2,977.61	N/A	N/A	($1.94) per share	-13.33
ROIV Roivant Sciences	$29.05M	264.87	N/A	N/A	$7.76 per share	1.46
RVMD Revolution Medicines	$742K	10,189.51	N/A	N/A	$11.09 per share	3.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-241.44%	N/A	-75.69%	7/30/2025 (Estimated)
CGON CG Oncology	-$48.61M	-$1.51	N/A	N/A	N/A	-10,642.98%	-18.97%	-15.36%	8/14/2025 (Estimated)
ROIV Roivant Sciences	$4.35B	-$0.25	N/A	N/A	N/A	-119.54%	-14.05%	-12.81%	8/6/2025 (Estimated)
RVMD Revolution Medicines	-$436.37M	-$4.00	N/A	N/A	N/A	N/A	-33.67%	-30.08%	8/6/2025 (Estimated)

Latest CGON, ROIV, RVMD, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million
3/25/2025	Q4 2024	CGON CG Oncology	-$0.37	-$0.48	-$0.11	-$0.48	$0.11 million	$0.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.67	4.67
CGON CG Oncology	N/A	35.32	35.32
ROIV Roivant Sciences	N/A	37.91	37.91
RVMD Revolution Medicines	N/A	14.24	14.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
CGON CG Oncology	26.56%
ROIV Roivant Sciences	64.76%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
CGON CG Oncology	7.40%
ROIV Roivant Sciences	7.90%
RVMD Revolution Medicines	8.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	143.29 million	Optionable
CGON CG Oncology	61	76.23 million	N/A	Optionable
ROIV Roivant Sciences	860	679.81 million	657.18 million	Optionable
RVMD Revolution Medicines	250	186.27 million	154.76 million	Optionable

CGON, ROIV, RVMD, and BBIO Headlines

Recent News About These Companies

Harbor Capital Advisors Inc. Acquires New Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

June 13 at 4:12 AM | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $67.08 Average Price Target from Brokerages

June 4, 2025 | americanbankingnews.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

June 1, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Buy" from Analysts

June 1, 2025 | marketbeat.com

22,725 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Jefferies Financial Group Inc.

May 30, 2025 | marketbeat.com

Voloridge Investment Management LLC Has $2.09 Million Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 30, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Shares Up 3.9% - Should You Buy?

May 29, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Trading Down 4% - Here's Why

May 28, 2025 | marketbeat.com

Polar Asset Management Partners Inc. Boosts Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 28, 2025 | marketbeat.com

Revolution Medicines’ SWOT analysis: stock shows promise amid clinical progress

May 27, 2025 | investing.com

Nuveen Asset Management LLC Raises Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 26, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Decreases Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 26, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by ProShare Advisors LLC

May 23, 2025 | marketbeat.com

Bank of America Corp DE Has $17.54 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 23, 2025 | marketbeat.com

Woodline Partners LP Has $169.96 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 22, 2025 | marketbeat.com

Soleus Capital Management L.P. Sells 503,500 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

May 21, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

May 21, 2025 | marketbeat.com

Revolution Medicines Inc.

May 20, 2025 | wsj.com

Tang Capital Management LLC Invests $4.37 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 20, 2025 | marketbeat.com

Tema Etfs LLC Invests $1.99 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 20, 2025 | marketbeat.com

Man Group plc Buys 65,567 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

May 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON, ROIV, RVMD, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$39.78 +0.13 (+0.33%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$40.72 +0.94 (+2.36%)

As of 06/13/2025 07:45 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

CG Oncology NASDAQ:CGON

$25.86 -0.64 (-2.42%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$26.92 +1.06 (+4.11%)

As of 06/13/2025 04:25 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Roivant Sciences NASDAQ:ROIV

$11.32 -0.15 (-1.31%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$11.30 -0.02 (-0.18%)

As of 06/13/2025 04:44 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Revolution Medicines NASDAQ:RVMD

$40.59 -0.52 (-1.26%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$40.50 -0.09 (-0.22%)

As of 06/13/2025 07:30 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time